In 2015, we started working on understanding mTOR, the target of several FDA approved inhibitors for kidney cancer. mTOR is responsible for regulating cell growth and metabolism and integrating signaling from a number of other genes that are commonly mutated in many other cancer types, as well.
mTOR itself is most commonly mutated in kidney cancer, but is also mutated in 2% of all other cancer types, potentially affecting millions of patients!
Projects 10491-10499 aim to help understand the effect these mutations, observed in the clinic, have on the structure and regulation of the protein. Understanding these mutants can provide a framework to understand which patients will respond to mTOR inhibitors already approved, and which mutants are best targeted by new drug development efforts.
Using Folding@home to understand the molecular mechanism of mTOR activating mutants in kidney cancer
mTOR, a serine/threonine kinase first discovered in 1994, is a key signaling node that integrates a number of inputs to control processes such as cell growth and metabolism, among others.…